N-[6-[2-[(5-Bromo-2-pyrimidinyl)oxy]ethoxy]-5-(2-methoxyphenoxy)-4-pyrimidinyl]-N'-(phenylmethyl)-sulfamide

ID: ALA2165328

Chembl Id: CHEMBL2165328

PubChem CID: 21979601

Max Phase: Preclinical

Molecular Formula: C24H23BrN6O6S

Molecular Weight: 603.46

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  COc1ccccc1Oc1c(NS(=O)(=O)NCc2ccccc2)ncnc1OCCOc1ncc(Br)cn1

Standard InChI:  InChI=1S/C24H23BrN6O6S/c1-34-19-9-5-6-10-20(19)37-21-22(31-38(32,33)30-13-17-7-3-2-4-8-17)28-16-29-23(21)35-11-12-36-24-26-14-18(25)15-27-24/h2-10,14-16,30H,11-13H2,1H3,(H,28,29,31)

Standard InChI Key:  LSQXFROVPNDBMN-UHFFFAOYSA-N

Associated Targets(Human)

EDNRB Tclin Endothelin receptor ET-B (1928 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
EDNRA Tclin Endothelin receptor ET-A (5008 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 603.46Molecular Weight (Monoisotopic): 602.0583AlogP: 3.73#Rotatable Bonds: 13
Polar Surface Area: 146.68Molecular Species: NEUTRALHBA: 10HBD: 2
#RO5 Violations: 1HBA (Lipinski): 12HBD (Lipinski): 2#RO5 Violations (Lipinski): 2
CX Acidic pKa: 7.24CX Basic pKa: 3.11CX LogP: 3.46CX LogD: 3.13
Aromatic Rings: 4Heavy Atoms: 38QED Weighted: 0.22Np Likeness Score: -1.00

References

1. Bolli MH, Boss C, Binkert C, Buchmann S, Bur D, Hess P, Iglarz M, Meyer S, Rein J, Rey M, Treiber A, Clozel M, Fischli W, Weller T..  (2012)  The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist.,  55  (17): [PMID:22862294] [10.1021/jm3009103]
2. Boss C, Bolli MH, Gatfield J..  (2016)  From bosentan (Tracleer®) to macitentan (Opsumit®): The medicinal chemistry perspective.,  26  (15): [PMID:27321813] [10.1016/j.bmcl.2016.06.014]

Source